Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

Werewolf continues to evaluate WTX-124 as a monotherapy and in combination with pembrolizumab through the ongoing Phase 1/1b clinical trial evaluating the INDUKINE molecule in multiple solid tumor ...

Reports Q4 revenue $0 vs. $301,590. “Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor ...

Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werew - Interim phase 1 clinical trial update reveals the clinical potential of ...

"Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor activity and tolerability for cytokine therapeutics as we completed the dose-escalation phase of ...

At close: March 13 at 4:00:02 PM EDT Loading Chart for HOWL ...